Compugen Ltd. Corporation

Medial Research Ltd.

Yaron Kinar

Zurit Levine

Amir Toporik

Liat Dassa

Shira Walach

Eve Montia

Sergey Nemzer

Anat Cohen-Dayag

Nir Kalkstein

Varda Shalev

Dalit Landesman-Milo

Inbal Goldshtein

Ofer Levy

Gad S Cojocaru

Shirley Sameah-Greenwald

Amit Novik

Galit Rotman

Merav Beiman

Marina Bubis

Avi Yeshah Rosenberg

Tania Pergam

Cynthia Koifman

Gabriel Chodick

Shirley Sameach- Greenwald

Shirley Sameach-Greenwald

Ofer Levi

Shira Wallach

Yael Furman

Sergey Nemzar

Dalit Milo

A method of evaluating lung cancer risk by generating a set of features comprising a plurality of current blood test results from a blood collected from a target individual, providing at least one classifier generated according to an analysis of a plurality of respective historical blood test results of each of another of a plurality of sampled individuals, and evaluating, using a processor, a lung cancer risk of said target individual by classifying said set of features using said at least one classifier. Each of said plurality of historical and current blood test results comprises results of one or more selected blood tests such as white blood cells blood test results, biochemistry test results, platelets blood test results including at least one of platelets count and mean platelet volume (MPV) and/or a combination of smoking history and red cell test results.

Methods and systems of evaluating a risk of lung cancer

A method of evaluating gastrointestinal cancer risk. The method comprises generating a set of features comprising a plurality of current blood test results from a blood collected from a target individual, providing at least one classifier generated according to an analysis of a plurality of respective historical blood test results of each of another of a plurality of sampled individuals, and evaluating, using a processor, a gastrointestinal cancer risk of the target individual by classifying the set of features using the at least one classifier.

Methods and systems of evaluating a risk of a gastrointestinal cancer

This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.

Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics

This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.

Growing community of inventors

Tel Aviv, Israel

Yaron Kinar